Accordingly, Rho-Kinase (ROCK) inhibitors are attractive treatment options in glaucoma therapy because of their multifunctional IOP-lowering effects [67,68], and might indicate the regulatory function of HTRA2 in this important pathway mechanism. The gene discussed is HTRA2; the disease is glaucoma.